ESR1 and breast cancer: Tamoxifen is the gold standard for the adjuvant treatment of breast cancer in pre‐ and postmenopausal patients with estrogen receptor alpha (ERα)‐positive tumors and is the first selective estrogen receptor modulator [5, 6].